Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results

Introduction. Apixaban is a direct oral anticoagulant prescribed for treatment and prevention of venous thromboembolism (VTE) and for prevention of stroke in patients with nonvalvular atrial fibrillation. Direct oral anticoagulants (DOACs) such as apixaban are rapidly replacing warfarin therapy due to improved efficacy and safety profile shown in clinical trials. However, anticoagulants can cause serious and adverse drug reactions (ADRs).

Aim. Study of the effect of carriage of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on the change in prothrombin time (PT) and activated partial thromboplastin time (aPTT) in patients using apixaban.

Materials and methods. A total of 36 patients were enrolled onto this prospective observational study. All patients received apixaban at doses in accordance with instructions on how to administer the drug. Atrial fibrillation was diagnosed in 26 patients, and secondary thrombotic complications in 23 patients. To perform pharmacogenetic tests and measure aPTT and PT parameters, venous blood samples from each patient were drawn on Days 4-5 after prescription of apixaban. The PharmGKB database was used to select candidate genes for the study. Genotyping was performed using the real-time polymerase chain reaction technique. Statistical analysis: data were analyzed by using IBM SPSS Statistics program, Version 23.0.

Results. In our study, we assessed the effect of polymorphisms in ABCB1 (rs1045738) C>T, ABCB1 (rs4148642) C>T genes on the aPTT and PT parameters. No statistically significant associations were found.

Conclusion. The differences between PT and APTT values in patients using apixaban in the groups with different polymorphisms in ABCB1 (rs1045738) C>T, ABCB1 (rs4148642) C>T gene were not statistically significant. Further studies are necessary to assess the effect of pharmacogenetics on the safety and efficacy profile of apixaban.

1. Seeger J., Wöhrle J. Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation. Core Evid. 2020;15:1–6. doi: 10.2147/CE.S172935.

2. Byon W., Garonzik S., Boyd R.A., Frost C.E. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–1279. doi: 10.1007/s40262-019-00775-z.

3. Granger C.B., Alexander J.H., McMurray J.J. V., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039.

4. Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106. doi: 10.1111/bcp.13299.

5. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393.

6. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–88. doi: 10.1093/ejcts/ezw313.

7. Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., Annest J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–1866. doi: 10.1001/jama.296.15.1858.

8. Tepper P.G., Mardekian J., Masseria C., Phatak H., Kamble S., Abdulsattar Y. et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One. 2018;13(11):e0205989. doi: 10.1371/journal.pone.0205989.

9. Adeboyeje G., Sylwestrzak G., Barron J.J., White J., Rosenberg A., Abarca J. et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):968–978. doi: 10.18553/jmcp.2017.23.9.968.

10. Garcia D.A., Fisher D.A., Mulder H., Wruck L., De Caterina R., Halvorsen S. et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020;221:1–8. doi: 10.1016/j.ahj.2019.10.013.

11. Brighton T. Experimental and clinical pharmacology: New oral anticoagulant drugs – mechanisms of action. Aust Prescr. 2010;33:38–41. doi: 10.18773/austprescr.2010.017.

12. Kubisz P., Stanciakova L., Dobrotova M., Samos M., Mokan M., Stasko J. Apixaban – Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):609–621. doi: 10.2174/1389200218666170424151551.

13. Ašić A., Marjanović D., Mirat J., Primorac D. Pharmacogenetics of novel oral anticoagulants: A review of identified gene variants & future perspectives. Per Med. 2018;15(3):209–221. doi: 10.2217/pme-2017-0092.

14. Hanigan S., Das J., Pogue K., Barnes G.D., Dorsch M.P. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–643. doi: 10.1007/s11239-020-02037–3.

15. Sychev D.A., Sychev I.N., Mirzaev K.B., Rytkin E.I., Ivashchenko D.V., Bure I.V. et al. Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: Focus on direct oral anticoagulants. Vestnik rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2019;74(5):299–306. (In Russ.) doi: 10.15690/vramn1214.

16. Sweezy T., Mousa S.A. Genotype-guided use of oral antithrombotic therapy: A pharmacoeconomic perspective. Vol. 11. Per Med. 2014;11(2): 223–235. doi: 10.2217/pme.13.106.

17. Raymond J., Imbert L., Cousin T., Duflot T., Varin R., Wils J., Lamoureux F. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11(1):37. doi: 10.3390/jpm11010037.

18. Dimatteo C., D’Andrea G., Vecchione G., Paoletti O., Tiscia G.L., Santacroce R. et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;145:24–26. doi: 10.1016/j.thromres.2016.07.005.

19. Kryukov A.V., Sychev D.A., Andreev D.A., Ryzhikova K.A., Grishina E.A., Ryabova A.V. et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43–49. doi: 10.2147/PGPM.S157111.

20. Ueshima S., Hira D., Kimura Y., Fujii R., Tomitsuka C., Yamane T. et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018;84(6):1301–1312. doi: 10.1111/bcp.13561.

21. Huppertz A., Grond-Ginsbach C., Dumschat C., Foerster K.I., Burhenne J., Weiss J. et al. Unexpected excessive apixaban exposure: Case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacol Toxicol. 2019;20(1):53. doi: 10.1186/s40360-019-0331-9.

22. Gulilat M., Keller D., Linton B., Pananos A.D., Lizotte D., Dresser G.K. et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis. 2020;49(2):294–303. doi: 10.1007/s11239-019-01962-2.

23. Conway S.E., Hwang A.Y., Ponte C.D., Gums J.G. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Vol. 37. Pharmacotherapy. 2017;37(2):236–248. doi: 10.1002/phar.1884.